Application of microsutures with vascular endothelial growth factor to improve vascular endothelial regeneration after small vessel anastomosis in the rats

doi:10.3969/j.issn.2095-4344.0062

Abstract

Abstract:

BACKGROUND: The vascular endothelial growth factor (VEGF) plays an important role in the development and formation of blood vessels. Up to now, there are few reports about the treatment of postoperative complications of vascular anastomosis surgery by mcrosutures with VEGF in China.

OBJECTIVE: To synthesiize microsutures with VEGF and to evaluate its effect in revascularization following small vessel anastomosis.

METHODS: The method of emulsification-diffusion was use to produce biodegradable polymer polylactic acid/glycolic acid (PLGA) copolymer microparticles containing VEGF, and then, the microparticles were added into microsutures to prepare microsutures with VEGF. Ninety Sprague-Dawley rats were enrolled to make animal models of caudal artery anastomosis using microsutures with VEGF in experimental group and microsutures alone in control group. Complications and VEGF level in the peripheral blood were detected and hematoxylin-eosin staining at the anastomotic site was performed at 2, 12 hours, 1, 3, 7 days after anastomosis.

RESULTS AND CONCLUSION: (1) Postoperative complications: The postoperative incidence of skin necrosis was significantly lower in the experimental group than the control group (P < 0.05). (2) VEGF level: Compared with the control group, the peripheral blood VEGF level was significantly higher in the experimental group at each time point after operation (P < 0.05). (3) Hematoxylin-eosin staining: In the experimental group, proliferated endothelial cells were seen near the anastomotic site at 1 day after anastomosis; there were a large number of proliferated endothelial cells and subcutaneous tissues covering the sutures completely at 3 days after anastomosis; and endothelial cells and internal elastic lamina were completely repaired, smooth muscle cells proliferated further, and the outer membrane returned to normal at 1 week after anastomosis. In the control group, cell degeneration and necrosis were seen near the anastomotic suture, and only adventitial cells infiltrated and exhibited a traumatic proliferative response at 1 day after anastomosis; neonatal endothelial cells appeared in the exfoliated area of the endothelial cells, grew and migrated, and there was a few endothelial cells covering the anastomotic site at 3 days after anastomosis; and newborn endothelial cells got over the anastomotic crack and covered the suture. To conclude, microsutures with sustained-release VEGF microparticles can promote endothelial cell regeneration in rats at the anastomotic site.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

Key words: Vascular Endothelial Growth Factors, Microsurgery, Microsomes, Tissue Engineering

CLC Number:

R318

Zhang Tie-hui, Liang Wu, Ren Yuan-fei, Dong Yu-jin, Yang Wen-feng, Shang Yao-hua, Li Ju-tao, Zhong Sheng. Application of microsutures with vascular endothelial growth factor to improve vascular endothelial regeneration after small vessel anastomosis in the rats[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(6): 877-882.

Figures/Tables 5

References

[1]Zhang L,Si T,Fischer AJ,et al.Coaxial Electrospray of Ranibizumab- Loaded Microparticles for Sustained Release of Anti-VEGF Therapies. PLoS One.2015;10(8):e0135608.

[2]Park K.Delivery of definable numbers of PLGA microparticles within embryoid bodies.J Control Release,.2013;168(1):103.

[3]Herrán E,Ruiz-Ortega JÁ,Aristieta A,et al.In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.Eur J Pharm Biopharm. 2013;85(3 Pt B):1183-1190.

[4]Simón-Yarza T,Tamayo E,Benavides C,et al.Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia.Int J Pharm.2013;454(2):784-790.

[5]White LJ,Kirby GT,Cox HC,et al.Accelerating protein release from microparticles for regenerative medicine applications.Mater Sci Eng C Mater Biol Appl.2013;33(5):2578-2583.

[6]Dhanda DS,Tyagi P,Mirvish SS,et al.Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.J Control Release.2013;168(3):239-250.

[7]Qutachi O,Shakesheff KM,Buttery LD,et al.Delivery of definable number of drug or growth factor loaded poly(DL-lactic acid-co-glycolic acid microparticles within human embryonic stem cell derived aggregates.J Control Release.2013;168(1):18-27.

[8]Bible E,Qutachi O,Chau DY,et al.Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles.Biomaterials.2012;33(30):7435-7446.

[9]Simón-Yarza T,Formiga FR,Tamayo E,et al.PEGylated-PLGA microparticles containing VEGF for long term drug delivery.Int J Pharm.2013;440(1):13-18.

[10]Xu H,Nguyen KT,Brilakis ES,et al.Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles.J Cardiovasc Transl Res. 2012;5(4):519-527.

[11]Formiga FR,Pelacho B,Garbayo E,et al.Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model.J Control Release.2010;147(1):30-37.

[12]Shahani K,Swaminathan SK,Freeman D,et al.Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention.Cancer Res.2010;70(11):4443-4452.

[13]Jay SM,Shepherd BR,Bertram JP,et al.Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation.FASEB J.2008;22(8):2949-2956.

[14]Amrite AC,Ayalasomayajula SP,Cheruvu NP,et al.Signgle periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage.Invest Ophthalmol Vis Sci.2006;47(3):1149-1160.

[15]Bandi N,Ayalasomayajula SP,Dhanda DS,et al.Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress,VEGFexpression, and vascular leakage in a benzo(a)pyrene-fed mouse model.J Pharm Pharmacol.2005;57(7):851-860.

[16]Chen Y,Luo X,Xiao J,et al.Experimental study on polylactic glycolate acid microparticles with releasing-slowly vascular endothelial growth factor.Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2005;19(4):262-263.

[17]Ayalasomayajula SP,Kompella UB.Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model.Eur J Pharmacol. 2005;511(2-3):191-198.

[18]陈扬,肖建德,李振宇,等.血管内皮生长因子缓释微粒的合成与制备[J].中国骨肿瘤骨病杂志,2006,3(3):150-151.

[19]沈素祥,美小涛,张绍东,等.rhBMP-2/无定形磷酸钙纳米缓释微粒成骨活性的实验研究[J].生物医学工程与临床杂志, 2008,3(12):175-178.

[20]潘兴纳,李亚雄,蒋立虹.组织工程血管支架材料的研究与进展[J].中国组织工程研究,2016,20(34):5149-5154.

[21]Gaitskell K,Martinek I,Bryant A,et al.Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev.2011;(9): CD007930.

[22]Kroep JR,Nortier JWR.The role of bevacizumab in advanced epithelial ovarian cancer.Curr Pharm Des.2012;18(25):3775-3783.

[23]Yamazaki Y,Morita T.Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 2006;10(4):515-527.

[24]Roy H,Bhardwaj S,Ylä-Herttuala S. Biology of vascular endothelial growth factors.FEBS Lett. 2006;580(12):2879-2887.

[25]Jackson MR,Carney EW,Lye SJ,et al.Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation.Placenta.1994;15(4):341-353.

[26]Wei MH,Popescu NC,Lerman MI,et al.Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12.Hum Genet.1996;97(6):794–797.

[27]Vincenti V,Cassano C,Rocchi M,et al.Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation.1996;93(8):1493-1495.

[28]Hsieh YY,Chang CC,Tsai FJ,et al.Tallele for VEGF-460 gene polymorphism at 5’-untranslated region is associated with higher susceptibility of leiomyoma.Biochem Genet.2008;46(5-6):356-361.

[29]Feng Y,Lin X,Zhou S,et al.The associations between the polymorphisms of the ER-α gene and the risk of uterine leiomyoma(ULM).Tumour Biol.2013;34(5):3077-3082.

[30]Hsieh YY,Chang CC,Tsai FJ,et al.Estrogen receptor thymine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma.Fertil Steril.2003;79(1):96-99.

[31]Yaghmaei M,Salimi S,Namazi L,et al.Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma-a case-control study.Genet Mol Biol. 2015;38(4): 444-449.

[32]Wang F,Chen J,Wang L,et al.CYP1A1 genetic polymorphisms and uterine leiomyoma risk: a meta-analysis.Int J Clin Exp Med. 2015;8(3): 3590-3594.

[33]Feng Y,Zhao X,Zhou C,et al.The associations between the Val158Met in the catechol-O-methyltransferase(COMT) gene and the risk of uterine leiomyoma(ULM). Gene.2013;529(2): 296-299.

[34]Salimi S,Hajizadeh A,Khodamian M,et al.Age-dependent association of MDM2 promoter polymorphisms and uterine leiomyoma in South-East Iran: A preliminary report.J Obstet Gynaecol Res.2015; 41(5):729-734.

[35]Stoner M,Wang F,Wormke M,et al.Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins.J Biol Chem. 2000;275(30):22769-22779.

[36]Adams J,Carder PJ,Downey S,et al.Vascular endothelial growth factor(VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.Cancer Res.2000;60(11):2898-2905.

[37]Chao Y,Li CP,Chau GY,et al.Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery.Ann Surg Oncol.2003;10(4):355-362.